Oppenheimer Starts Pacira Pharmaceuticals (PCRX) at Outperform

Oppenheimer analyst Les Sulewski initiates coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Outperform rating and a price target of $32.00.

The analyst comments "We initiate coverage of Pacira BioSciences with an Outperform rating and $32 PT. We believe Exparel is entering a stronger commercial phase as expanding separate reimbursement, outpatient procedure migration, and GPO normalization improve the conversion of volume gains into reported sales. The Fresenius settlement on gExparel with volume limits creates a manageable generic transition beginning in 2030, while Zilretta is emerging as a more meaningful second growth driver. PCRX-201 provides potentially transformative knee OA optionality, with the first randomized controlled Ph2 data expected by YE26 and no revenue included in our base-case forecasts. Strong cash generation should support continued pipeline investment and disciplined capital allocation."

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $24.70 yesterday.

You May Also Be Interested In

• Oppenheimer Assumes Inova Technology, Inc. (INVA) at Outperform
• Elemental Royalty Corp (ELE) PT Lowered to $31 at H.C. Wainwright
• Rubrik Inc (RBRK) PT Raised to $139 at Baird